The Bellvitge Hospital, Primary Care and IDIBELL have analyzed the cases of more than 77,500 heart failure patients in Catalonia between 2015 and 2019.
A research work led by neuroradiologists and neurologists from IDIBELL, the Bellvitge University Hospital, and the Institute of Diagnostic Imaging identified a new magnetic resonance biomarker. This biomarker would make it possible to accurately detect the focus of chronic brain inflammation, associated with the progressive form of multiple sclerosis.
Imaging biomarker may help to better understand and treat progressive multiple sclerosis Read More »
In a phase 2 clinical trial, researchers have observed that this combination allows to carry out global treatment from the beginning, manages to keep metastases stable for 7
Led by the Centre for Research and Technology Hellas (CERTH), the project includes 27 complementary partners from different research domains. This initiative integrates cutting-edge research methodologies powered by artificial intelligence to deliver personalized, evidence-based approaches for preventing this type of cancer.
The results of five studies have been reviewed, two of them randomized clinical trials, with a total of 691 episodes of febrile neutropenia. The effects of the use of beta-lactam antibiotics in intermittent infusions have been compared with prolonged infusions.
Dr. Josep Manuel Menchon, group leader at IDIBELL and head of the Psychiatry Service at Bellvitge University Hospital, participates in a pioneering study led by the University of Hertfordshire to address and reduce the risks of harmful Internet use among adolescents.
New research will look for risk indicators of harmful internet use among adolescents Read More »
The article by Juvé and Adamuz highlights the importance of knowledge of nursing tools and strategies (ATIC and ARES) to improve patient outcomes and the work environment.
The participation of Institute students in the IDIBELL sLHam for women scientists, the creation of a new Sant Jordi award or the co-creation of content and activities for the new Biomedicine subject have been the main novelties of the course.
According to the results of the APRIL study, in which the Hospital de Bellvitge and IDIBELL have participated, ApTOLL has shown good safety in 151 patients with acute ischemic stroke.
A new neuroprotective drug shows good preliminary results for ischemic stroke Read More »
In 2022, with almost 1,500 published articles, of which almost 600 were led by IDIBELL researchers, our research maintained its high level of quality and excellence, with an average impact factor greater than nine.
